FibroGen Inc. (FGEN) Leaped To A New High On Phase 2 Study Results

FibroGen Inc. (FGEN) announced after the bell Monday that its Phase 2 study of pamrevlumab in patients with idiopathic pulmonary fibrosis met the primary efficacy endpoint.

from RTT - Before the Bell http://ift.tt/2hKoWhk
via IFTTT